文献速递免疫规划卫生政策与健康促进

COVID-19疫苗不良反应频率与发生时间:多国队列事件监测研究

Frequency and timing of adverse reactions to COVID-19 vaccines; A multi-country cohort event monitoring study.
PubMed 文献 · Vaccine · 2024-03-06

该研究在2021年2月至2023年2月期间于多个欧洲国家开展队列事件监测,分析COVID-19疫苗第1剂、第2剂和加强针接种后患者报告不良药物反应(ADR)的频率、预测因素及发生与恢复时间。共29,837名参与者完成第1、2剂接种的基线和首次随访问卷,7,250名完成加强针问卷;至少报告一种ADR的比例为74.32%(95%CI 73.82-74.81),严重ADR在第1、2剂为0.24%(95%CI 0.19-0.31),加强针为0.26%(95%CI 0.15-0.41)。

要点

  • 至少报告一种ADR的参与者比例为74.32%(95%CI 73.82-74.81)。
  • 严重ADR比例第1、2剂为0.24%(95%CI 0.19-0.31),加强针为0.26%(95%CI 0.15-0.41)。
  • ADR发生时间中位数第1剂为14小时,第2剂和加强针略长;恢复时间一般在数天内。

核心结论

  • 尽管存在研究设计和研究实施方面的局限性,队列事件监测研究能够以患者为中心的角度对药物安全性进行及时且近乎实时的观察,在COVID-19大流行等紧急情况下对监管机构可发挥关键作用。

研究设计与样本

  • 队列事件监测研究于2021年2月至2023年2月在荷兰、比利时、法国、英国、意大利、葡萄牙、罗马尼亚、斯洛伐克和西班牙等多个欧洲国家开展。
  • 共29,837名参与者完成第1剂和第2剂接种的基线和首次随访问卷,7,250名参与者完成加强针问卷。
  • 分析包括对第1剂、第2剂和加强针接种后COVID-19疫苗相关ADR频率的描述性分析、使用广义线性混合效应模型分析发生ADR的潜在预测因素、ADR发生时间(TTO)和恢复时间(TTR)分析以及失访(L2FU)敏感性分析。

主要发现

  • 至少报告一种ADR的参与者比例为74.32%(95%CI 73.82-74.81)。
  • 包括注射部位反应在内的征集性ADR在各接种时间点均非常常见。
  • 这些反应的潜在预测因素包括使用的疫苗品牌、患者年龄、性别和既往SARS-CoV-2感染。
  • 严重ADR比例第1剂和第2剂为0.24%(95%CI 0.19-0.31),加强针为0.26%(95%CI 0.15-0.41)。
  • TTO中位数第1剂为14小时,第2剂和加强针略长;TTR一般在数天内;失访对频率估计的影响有限。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文提及存在因研究设计和研究实施所致的某些局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: During the COVID-19 pandemic, EMA set-up a large-scale cohort event monitoring (CEM) system to estimate incidence rates of patient-reported adverse drug reactions (ADRs) of different COVID-19 vaccines across the participating countries. This study aims to give an up to date and in-depth analysis of the frequency of patient-reported ADRs after the 1st, 2nd, and booster vaccination, to identify potential predictors in developing ADRs and to describe time-to-onset (TTO) and time-to-recovery (TTR) of ADRs. METHODS: A CEM study was rolled out in a period ranging from February 2021 to February 2023 across multiple European countries; The Netherlands, Belgium, France, the United Kingdom, Italy, Portugal, Romania, Slovakia and Spain. Analysis consisted of a descriptive analyses of frequencies of COVID-19 vaccine-related ADRs for 1st, 2nd and booster vaccination, analysis of potential predictors in developing ADRs with a generalized linear mixed-effects model, analysis of TTO and TTR of ADRs and a sensitivity analysis for loss to follow-up (L2FU). RESULTS: A total of 29,837 participants completed at least the baseline and the first follow-up questionnaire for 1st and 2nd vaccination and 7,250 participants for the booster. The percentage of participants who reported at least one ADR is 74.32% (95%CI 73.82-74.81). Solicited ADRs, including injection site reactions, are very common across vaccination moments. Potential predictors for these reactions are the brand of vaccine used, the patient's age, sex and prior SARS-CoV-2 infection. The percentage of serious ADRs in the study is low for 1st and 2nd vaccination (0.24%, 95%CI 0.19--0.31) and booster (0.26%, 95%CI 0.15, 0.41). The TTO was 14 h (median) for dose 1 and slightly longer for dose 2 and booster dose. TTR is generally also within a few days. The effect of L2FU on estimations of frequency is limited. CONCLUSION: Despite some limitations due to study design and study-roll out, CEM studies can allow prompt and almost real-time observations of the safety of medications directly from a patient-centered perspective, which can play a crucial role for regulatory bodies during an emergency setting such as the COVID-19 pandemic.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Raethke M, van Hunsel F, Luxi N, et al. Frequency and timing of adverse reactions to COVID-19 vaccines; A multi-country cohort event monitoring study. Vaccine. 2024. PMID: 38448322. doi:10.1016/j.vaccine.2024.03.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。